Our group studies breast tumor initiation and progression; from the cell of origin in which the first oncogenic events take place, the specific pathways and processes that are deregulated in the further progression of the tumors, to the specific events that are essential for the transition from in situ to invasive cancer. We use patient cohorts and animal models (transgenic and patient-derived xenograft - PDX). We apply high-throughput genomic technologies, functional assays, lineage-tracing, in situ hybridization techniques and statistical and bioinformatics methods in our research.
Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials
Acta Oncol, 57 (1), 38-43
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
Breast Cancer Res, 19 (1), 120